Featured Research

from universities, journals, and other organizations

How Receptors Govern Inflammatory Pain

Date:
December 2, 2004
Source:
Cell Press
Summary:
Researchers have shown in animal studies how receptors on nerve cells can become altered to produce chronic pain triggered by inflammation. They say that their findings could aid in developing new drugs to treat such chronic pain, which is distinct from the relatively short-lived pain from injury, which fades as the injury heals.

Researchers have shown in animal studies how receptors on nerve cells can become altered to produce chronic pain triggered by inflammation. They say that their findings could aid in developing new drugs to treat such chronic pain, which is distinct from the relatively short-lived pain from injury, which fades as the injury heals.

In their experiments, Bettina Hartmann and her colleagues studied receptors called AMPA receptors, which are triggered by the neurotransmitter glutamate. Such receptors are protein switches that nestle in the membranes of nerve cells and, when triggered, induce either short-term or long-term changes in the nerve cells. A short-term change might be the triggering of a single nerve impulse; but AMPA receptors have been implicated in long-lasting changes such as adjusting the strength of nerve cell connections, or synapses, in learning and memory. AMPA receptors regulate nerve cell response by opening to enhance calcium flow into the cell, heightening the cells' sensitivity to producing nerve impulses when triggered.

According to Hartmann and her colleagues, studies of spinal cord tissue showed that AMPA receptors are found in spinal cord regions known to be responsible for pain sensing, or nociception. However, they said, there had been no studies that explored what role the receptors played in whole animals.

To study that role, the researchers genetically altered mice to lack one or another type of key component, or subunit, of the AMPA receptor protein. Knocking out one type of subunit, called GluR-A, would enhance AMPA permeability to calcium; and knocking out the other, called GluR-B, would reduce its permeability. Normally, the relative fraction of AMPA receptors with GluR-A or GluR-B on the surfaces of nerve cells would determine the cell's permeability to calcium.

Importantly, the researchers found that both of the types of deficient mice showed normal response to discomforting stimuli, such as heat. Thus, their pain responses were otherwise normal.

However, when the researchers used chemicals to induced an artificial inflammation in the paws of the deficient mice, they found significant differences in responses between the two mutant mouse strains. The strain with increased permeability of their AMPA channels was significantly more sensitive to heat or mechanical pressure on their inflamed paws than were either the strain of mice with "closed" AMPA channels or the normal mice.

In similar tests, the researchers also found that the altered mice with more permeable AMPA channels showed evidence of greater persisting pain from inflammation, compared with the altered mice with less permeable channels. According to Hartmann and her colleagues, this difference "supports that acute, short-term plasticity at central nociceptive synapses is dependent on AMPA receptors and their composition."

The researchers also cited evidence from other laboratories that AMPA receptors might be involved in pain-related changes in the brain that are "involved in the perception, memory, and emotional modulation of pain."

The researchers concluded that "the present study demonstrates that AMPA receptors are important determinants of pathological nociceptive sensitivity and suggests their potential relevance in the therapeutic approaches toward the prevention and treatment of chronic inflammatory pain.

Bettina Hartmann, Seifollah Ahmadi, Paul A. Heppenstall, Gary R. Lewin, Claus Schott, Thilo Borchardt, Peter H. Seeburg, Hanns Ulrich Zeilhofer, Rolf Sprengel, and Rohini Kuner: "The AMPA Receptor Subunits GluR-A and GluR-B Reciprocally Modulate Spinal Synaptic Plasticity and Inflammatory Pain"

Publishing in Neuron, Volume 44, Number 4, November 18, 2004, pages 637–650. http://www.neuron.org.


Story Source:

The above story is based on materials provided by Cell Press. Note: Materials may be edited for content and length.


Cite This Page:

Cell Press. "How Receptors Govern Inflammatory Pain." ScienceDaily. ScienceDaily, 2 December 2004. <www.sciencedaily.com/releases/2004/11/041123163648.htm>.
Cell Press. (2004, December 2). How Receptors Govern Inflammatory Pain. ScienceDaily. Retrieved October 1, 2014 from www.sciencedaily.com/releases/2004/11/041123163648.htm
Cell Press. "How Receptors Govern Inflammatory Pain." ScienceDaily. www.sciencedaily.com/releases/2004/11/041123163648.htm (accessed October 1, 2014).

Share This



More Health & Medicine News

Wednesday, October 1, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Some Positive Ebola News: Outbreak 'Contained' In Nigeria

Some Positive Ebola News: Outbreak 'Contained' In Nigeria

Newsy (Sep. 30, 2014) The CDC says a new case of Ebola has not been reported in Nigeria for more than 21 days, leading to hopes the outbreak might be nearing its end. Video provided by Newsy
Powered by NewsLook.com
UN Ebola Mission Head: Immediate Action Is Crucial

UN Ebola Mission Head: Immediate Action Is Crucial

AFP (Sep. 30, 2014) The newly appointed head of the United Nations Mission for Ebola Emergency Response (UNMEER), Anthony Banbury, outlines operations to tackle the virus. Duration: 00:39 Video provided by AFP
Powered by NewsLook.com
CDC Confirms First Case of Ebola in US

CDC Confirms First Case of Ebola in US

AP (Sep. 30, 2014) The CDC has confirmed the first diagnosed case of Ebola in the United States. The patient is being treated at a Dallas hospital after traveling earlier this month from Liberia. (Sept. 30) Video provided by AP
Powered by NewsLook.com
New Breast Cancer Drug Extends Lives In Clinical Trial

New Breast Cancer Drug Extends Lives In Clinical Trial

Newsy (Sep. 30, 2014) In a clinical trial, breast cancer patients lived an average of 15 months longer when they received new drug Perjeta along with Herceptin. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:

Strange & Offbeat Stories


Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins